TY - JOUR
T1 - Specifications of the ACMG/AMP Variant Curation Guidelines for Hereditary Hemorrhagic Telangiectasia Genes - ENG and ACVRL1
AU - Demille, Desiree
AU - McDonald, Jamie
AU - Bernabeu, Carmelo
AU - Racher, Hilary
AU - Olivieri, Carla
AU - Cantarini, Claudia
AU - Sbalchiero, Anna
AU - Thompson, Bryony A.
AU - Jovine, Luca
AU - Shovlin, Claire L.
AU - Dupuis-Girod, Sophie
AU - Lesca, Gaetan
AU - Tusseau, Maud
AU - Ganguly, Arupa
AU - Kasthuri, Raj S.
AU - Jessen, Jaime
AU - Massink, Maarten P.G.
AU - Ichikawa, Shoji
AU - Bayrak-Toydemir, Pinar
N1 - Publisher Copyright:
© 2024 Desiree DeMille et al.
PY - 2024
Y1 - 2024
N2 - The 2015 ACMG/AMP standards and guidelines for interpretation of sequence variants are widely used by laboratories, including for variant curation of the hereditary hemorrhagic telangiectasia (HHT) genes. However, the need for gene- and disease-specific modifications and specifications of these general guidelines to optimize and standardize variant classification was recognized at the time of publication. With this goal, the ClinGen HHT variant curation expert panel was formed. Here, we describe our recommended HHT-specific variant classification criteria and the outcomes from pilot testing of 30 variants of the ENG and ACVRL1 genes. Eight of the original ACMG/AMP rules were determined to not be applicable for ENG- or ACVRL1-related HHT or were previously recommended by ClinGen for removal, two rules were unmodified, and the remaining 18 rules were modified according to HHT specifications or previous ClinGen general recommendations. This study demonstrates the importance of HHT-specific criteria in the optimization and standardization of HHT variant classification and conflicting classification resolution.
AB - The 2015 ACMG/AMP standards and guidelines for interpretation of sequence variants are widely used by laboratories, including for variant curation of the hereditary hemorrhagic telangiectasia (HHT) genes. However, the need for gene- and disease-specific modifications and specifications of these general guidelines to optimize and standardize variant classification was recognized at the time of publication. With this goal, the ClinGen HHT variant curation expert panel was formed. Here, we describe our recommended HHT-specific variant classification criteria and the outcomes from pilot testing of 30 variants of the ENG and ACVRL1 genes. Eight of the original ACMG/AMP rules were determined to not be applicable for ENG- or ACVRL1-related HHT or were previously recommended by ClinGen for removal, two rules were unmodified, and the remaining 18 rules were modified according to HHT specifications or previous ClinGen general recommendations. This study demonstrates the importance of HHT-specific criteria in the optimization and standardization of HHT variant classification and conflicting classification resolution.
UR - http://www.scopus.com/inward/record.url?scp=85194373910&partnerID=8YFLogxK
U2 - 10.1155/2024/3043736
DO - 10.1155/2024/3043736
M3 - Article
AN - SCOPUS:85194373910
SN - 1059-7794
VL - 2024
JO - Human mutation
JF - Human mutation
M1 - 3043736
ER -